MedTrace Logo

Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial

NCT00337181 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2018-08-22

Study results available
· View outcomes & findings →

Summary

This protocol will study the clinical course of HIV-infection among volunteers who have received either a placebo injection or the experimental vaccine combination of ALVAC-HIV and AIDSVAX B/E prior to HIV-1 infection in reference to study NCT00223080 RV144. The study will assess whether those who received the experimental vaccine combination have a slower progression of HIV disease compared to those who received the placebo injection.

Conditions

Sponsors & Collaborators

  • Walter Reed Army Institute of Research (WRAIR)

    collaborator FED

  • Royal Thai Ministry of Public Health

    collaborator UNKNOWN

  • Mahidol University

    collaborator OTHER

  • Armed Forces Research Institute of Medical Sciences, Thailand

    collaborator OTHER_GOV

  • Sanofi Pasteur, a Sanofi Company

    collaborator INDUSTRY

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Supachai Rerks-Ngarm, MD · Ministry of Health, Thailand

Eligibility

Min Age
18 Years
Max Age
31 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2011-03-01
Completion
2011-06-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00337181 on ClinicalTrials.gov